Core Viewpoint - The company Wangshan Wangshui-B (02630.HK) is set to list on the Hong Kong Stock Exchange on November 6, with significant pre-listing trading activity indicating strong investor interest and potential profitability for investors [1][3]. Company Overview - Wangshan Wangshui was established in 2013 and operates in the biopharmaceutical sector, with nine innovative drug pipelines, two of which are in commercialization, four in clinical stages, and three in preclinical stages [5]. - The company's two core products are LV232, aimed at treating severe depression, and TPN171, a PDE5 inhibitor for erectile dysfunction (ED) [5]. Product Details - LV232 is expected to reduce gastrointestinal side effects compared to existing antidepressants, with a Phase II clinical trial in China starting in April 2025 and completion anticipated in the second half of 2026 [5]. - TPN171 has been approved in Uzbekistan since September 2022 and is expected to be approved in China by July 2025, with a projected global market size for PDE5 inhibitors of $10.6 billion in 2024, growing to $11.2 billion by 2035 [5][6]. Financial Performance - For the fiscal years 2023 and 2024, the company reported revenues of 200 million and 11.83 million, respectively, with net profits of 64.27 million and a loss of 218 million [6]. - The first four months of 2025 showed revenues of 12.96 million and a net loss of 11.2 million, with significant R&D expenditures related to core products [6][7]. Market Trends - The Hong Kong stock market has seen a resurgence in new IPOs, with 14 new stocks listed in October, of which only one experienced a decline on its first trading day [9]. - The average daily trading volume in Hong Kong has exceeded $32 billion this year, doubling from the previous year, with a total of 80 IPOs raising over $26 billion [9][10].
暴涨超190%，港股异动